Sorafenib - a small molecule with big promise?

Leuk Lymphoma. 2010 Feb;51(2):181-2. doi: 10.3109/10428190903470893.
No abstract available

Publication types

  • Comment

MeSH terms

  • Abdominal Pain / chemically induced
  • Acute Disease
  • Area Under Curve
  • Benzenesulfonates / adverse effects
  • Benzenesulfonates / pharmacokinetics
  • Benzenesulfonates / therapeutic use*
  • Diarrhea / chemically induced
  • Dose-Response Relationship, Drug
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Fatigue / chemically induced
  • Humans
  • Leukemia, Myeloid / drug therapy*
  • Leukemia, Myeloid / metabolism
  • Leukemia, Myeloid / pathology
  • Metabolic Clearance Rate
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / metabolism
  • Myelodysplastic Syndromes / pathology
  • Nausea / chemically induced
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Phosphorylation / drug effects
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / pharmacokinetics
  • Protein Kinase Inhibitors / therapeutic use
  • Pyridines / adverse effects
  • Pyridines / pharmacokinetics
  • Pyridines / therapeutic use*
  • Sorafenib
  • Treatment Outcome

Substances

  • Benzenesulfonates
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Pyridines
  • Niacinamide
  • Sorafenib
  • Extracellular Signal-Regulated MAP Kinases